Diabetes / Zuckerstoffwechsel

Focused diabetes and glucose metabolism screen combining fasting glucose, HbA1c, and related metabolic markers. At under €47 all-inclusive, an affordable targeted panel for diabetes risk assessment and monitoring.

This panel targets glucose metabolism specifically, combining the two primary diabetes screening markers — fasting glucose and HbA1c — for maximum diagnostic sensitivity. Using both markers together catches cases that either one alone would miss. Fasting glucose provides a point-in-time measurement of blood sugar regulation. Normal fasting glucose is below 100 mg/dL (5.6 mmol/L), impaired fasting glucose (pre-diabetes) is 100-125 mg/dL, and diabetes is diagnosed at 126 mg/dL or above on two separate occasions. However, fasting glucose can be influenced by acute stress, recent meals (if fasting was incomplete), medications, and time of day — a single measurement has limited sensitivity for detecting early glucose dysregulation. HbA1c compensates for these limitations by reflecting average glycaemia over the preceding 8-12 weeks. It is unaffected by fasting status, time of day, or acute stress. The diagnostic thresholds are well established: below 5.7% is normal, 5.7-6.4% indicates pre-diabetes, and 6.5% or above meets the diabetes criterion. The combination of a normal fasting glucose with an HbA1c of 5.7-6.0% is a common finding that would be missed by either test alone — it identifies individuals with postprandial glucose excursions who have not yet developed fasting hyperglycaemia. Pre-diabetes is the critical intervention window. The Diabetes Prevention Program demonstrated that lifestyle modification (150 minutes per week of moderate exercise, 5-7% weight loss) reduces progression to type 2 diabetes by 58% — more effective than metformin (31% reduction). Germany has an estimated 7-8 million people with pre-diabetes, the majority undiagnosed. For patients already diagnosed with diabetes, this panel serves as a monitoring tool. HbA1c every 3-6 months tracks treatment effectiveness against individualised targets (typically below 7.0% for most adults, with relaxed targets for elderly or complex patients). Changes in HbA1c of 0.3% or more are generally considered clinically significant. HbA1c has known limitations: it can be falsely low with haemolytic anaemia, significant blood loss, or chronic kidney disease on dialysis, and falsely high with iron deficiency. For these populations, fructosamine or continuous glucose monitoring may be more appropriate.